Skip to main content

The contract manufacturing market for Pharmaceuticals in China is estimated to be worth USD 13 billion in 2030, predicts Roots Analysis

 

Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030.”

 

The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China. The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region. Amongst other elements, the report features:

§  A detailed assessment of the current market landscape of pharmaceutical contract manufacturers in China engaged in the development of active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs). 

§  A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.

§  A brief discussion of various regulatory guidelines in China and various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.

§  Detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China.

§  A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues).

§  An analysis of the partnerships and acquisitions that have been established in this domain, in the recent past.

§  A detailed capacity analysis based on the installed reactor capacities of the manufacturing facilities in China.

§  A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Key Geographical Regions

  • Eastern China
  • Southern China
  • Northern China 

 

§  Type of Product

 

§  Type of Drug Product

  • Solid
  • Liquid / Semi-Solid
  • Injectable
  • Others

 

§  Scale of Operation

  • Clinical
  • Commercial

 

To Request for sample report - https://www.rootsanalysis.com/reports/312/request-sample.html

 

§  Company Size

  • Small
  • Mid-Sized
  • Large / Very Large

 

 

Key players covered in the report

§  2Y-Chem

§  Aurisco Pharmaceutical

§  ChemPartner

§  Dorrapharma

§  Hubei Biocause Pharmaceutical

§  Infoark

§  Ningbo Menovo Pharmaceutical

§  Shandong Xinhua Pharmaceutical

§  Shanghai Acebright Pharmaceuticals

§  STA Pharmaceutical

§  Zhejiang Huahai Pharmaceutical

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

 

Other Recent Offerings

1.     China Biopharmaceutical Contract Manufacturing Market, 2020 – 2030

2.     HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030

3.     Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

 

 

Labels:

Comments

Post a Comment

Popular posts from this blog

The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis

  Roots Analysis has announced the addition of “ Gene Therapy Market (4th Edition), 2020-2030” report to its list of offerings.   Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.   To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html   Key Market Insights   Around 800 gene therapies are currently being developed across different stages Apart from 10 approved products, most of the aforementioned therapies (65%) are in the early stages of developmen...
Post a Comment
Read more

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030, predicts Roots Analysis

  Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways ”.   The   report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape, providing information on drug developer(s) phase of development, type of ...
Post a Comment
Read more

The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.

  Key Inclusions §   A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of packaging and number of manufacturing facilities. §   A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs. §   A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China. §   Elaborate profiles of key players that offer a diverse range of capabilities for the manufacturing of p...
Post a Comment
Read more